Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kalinova, Slavka
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes	Active, not recruiting	4	780	Europe, Canada, US, RoW	Tirzepatide, LY3298176, Antihyperglycemic medication	Eli Lilly and Company	Type 2 Diabetes	10/25	11/27
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Overweight and Obesity	02/29	02/29